Methods and compositions for administration of TRPV1 agonists
AssigneeAcorda Therapeutics, Inc.
InventorsNaweed Muhammad, Gene Curtis Jamieson, Keith R. Bley, Sanjay Chanda
Life of this patent
Estimating the term…
Abstract
Compositions are provided that contain a TRPV1 agonist, such as capsaicin, and a solvent system. Topical application of the composition results in rapid delivery of agonist to the dermis and epidermis. Method of using the compositions for reducing nociceptive nerve fiber function in subjects, and for treatment of capsaicin-responsive conditions are also provided.
Claims84
A method of delivering a TRPV1 agonist to the epidermis and dermis underlying a 1 cm2 area of a skin or mucosal surface of a mammal, comprising non-occlusively or non-adherently contacting the area with a composition comprising the TRPV1 agonist and at least one penetration enhancer, wherein 30 minutes after said contacting at least about 3 nmoles of the TRPV1 agonist is retained in the epidermis and dermis.
A method of reducing the density of functional nociceptive nerve fibers in a selected region of a subject, comprising non-occlusively or non-adherently contacting the selected region with an immediate-release composition that comprises a TRPV1 agonist and one or more penetration enhancers, wherein said composition delivers at least about 3 nmoles of the TRPV1 agonist to skin as measured in a mouse skin absorption assay.
A method of reducing the density of functional nociceptive nerve fibers in a selected region of a subject, comprising non-occlusively or non-adherently contacting the selected region with a composition that comprises a TRPV1 agonist and a solvent system comprising one or more penetration enhancers, wherein said composition delivers at least about 3 nmoles of the TRPV1 agonist to skin as measured in a mouse skin absorption assay, and wherein at least about 5 μl of the composition is delivered to each cm2 of the selected region in about 15 minutes.
A method of treating a capsaicin-responsive condition in a subject, comprising non-occlusive or non-adherent administration of a composition that comprises a TRPV1 agonist and at least one penetration enhancer, wherein said composition delivers at least about 3 nmoles of the TRPV1 agonist to skin as measured in a mouse skin absorption assay.
Dependencies are inferred from the claim text.